Precision Radiotherapy for Non-Small Cell Lung Cancer

(ASPIRE-ILD Trial)

Recruiting in Palo Alto (17 mi)

+5 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's

No Placebo Group

Approved in 4 Jurisdictions

Trial Summary

What is the purpose of this trial?

This is a prospective phase II study of Stereotactic Ablative Radiotherapy (SABR) in patients with Non-Small Cell Lung Cancer (NSCLC) and co-existent Interstitial Lung Disease (ILD), to determine oncologic and toxicity outcomes. Patients will be divided into 3 separate cohorts based on the ILD-GAP index.

Research Team

Alexander Louie, MD

Principal Investigator

London Health Sciences Centre, Lawson Health Research Institute

Chris Ryerson, MD

Principal Investigator

University of British Columbia

David Palma, MD

Principal Investigator

London Health Sciences Centre, Lawson Health Research Institute

Eligibility Criteria

This trial is for adults over 18 with early-stage Non-Small Cell Lung Cancer (NSCLC) and Interstitial Lung Disease (ILD). They should not be candidates for surgery, have a life expectancy of more than 6 months, and an ECOG performance status of 0-3. Excluded are those with other recent cancers, prior thoracic radiotherapy, or taking certain drugs that affect radiotherapy.

Inclusion Criteria

I can care for myself but may not be able to do heavy physical work.

My cancer is early stage, with a tumor size of 5 cm or less and hasn't spread.

I am diagnosed with non-small cell lung cancer, but it's not confirmed by pathology.

Exclusion Criteria

I am not taking any medications known to increase sensitivity to radiation.

I plan to only receive the study treatment unless my disease gets worse.

I plan to continue my current treatment for lung fibrosis while in this study.

Treatment Details

Interventions

• Stereotactic Ablative Radiotherapy (Proton Beam Therapy)

Trial Overview The study tests Stereotactic Ablative Radiotherapy (SABR) on NSCLC patients with ILD to see its effectiveness and safety. Participants are grouped based on their ILD-GAP index to assess outcomes specific to their condition's severity.

Participant Groups

Group I: Treatment Arm: Stereotactic Ablative Radiotherapy Experimental Treatment 1 Intervention

Stereotactic ablative radiotherapy for early non-small cell lung cancer and interstitial lung disease

Who Is Running the Clinical Trial?

London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's

Lead Sponsor

Trials

686

Recruited

427,000+

Dr. Alex Barron

London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's

Chief Medical Officer since 2023

MD from Western University

David Musyj

London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's

Chief Executive Officer

Physiotherapy degree

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Lead Sponsor

Trials

678

Recruited

421,000+

Lisa Porter

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Chief Medical Officer

PhD in Biomedical Sciences

Roy Butler

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Chief Executive Officer

PhD in Health Sciences

London Health Sciences Centre OR Lawson Research Institute of St. Joseph's

Lead Sponsor

Trials

668

Recruited

424,000+

Roy Butler

London Health Sciences Centre OR Lawson Research Institute of St. Joseph's

Chief Executive Officer

PhD in Health Sciences

Dr. Cindy Hutnik

London Health Sciences Centre OR Lawson Research Institute of St. Joseph's

Chief Medical Officer

MD, PhD

Lawson Health Research Institute

Lead Sponsor

Trials

684

Recruited

432,000+

Dr. Michael Strong

Lawson Health Research Institute

Chief Medical Officer

MD

Roy Butler

Lawson Health Research Institute

Chief Executive Officer

PhD in Health Sciences

Western University, Canada

Collaborator

Trials

270

Recruited

62,500+

Dr. Robin Farias-Eisner

Western University, Canada

Chief Executive Officer since 2022

PhD in Molecular Biology from UCLA, MD from the Royal College of Surgeons in Dublin, MBA from Pepperdine University

James Tweedy

Western University, Canada

Chief Medical Officer since 2020

MBA from Trinity Western University

London Health Sciences Centre

Collaborator

Trials

151

Recruited

60,400+

Dr. Alex Barron

London Health Sciences Centre

Chief Medical Officer since 2023

MD from Western University

David Musyj

London Health Sciences Centre

Chief Executive Officer

Bachelor of Laws (LLB) from the University of Windsor

University of British Columbia

Collaborator

Trials

1,506

Recruited

2,528,000+

Dr. Christopher Haqq

University of British Columbia

Chief Medical Officer since 2019

MD, University of British Columbia

Bekki Bracken Brown

University of British Columbia

Chief Executive Officer since 2023

Bachelor's degree from Duke University

University of Western Ontario, Canada

Collaborator

Trials

168

Recruited

320,000+

Michael Crackower

University of Western Ontario, Canada

Chief Scientific Officer since 2018

B.Sc. in Biochemistry from the University of Western Ontario

Lisa Cechetto

University of Western Ontario, Canada

Executive Director since 2021

Master’s of Science from McMaster University, dual executive MBAs from the Kelley School of Business, Indiana University and Sungkyunkwan University